...
首页> 外文期刊>Drug delivery and translational research >The incorporation of water-soluble gel matrix into bile acid-based microcapsules for the delivery of viable beta-cells of the pancreas, in diabetes treatment: biocompatibility and functionality studies
【24h】

The incorporation of water-soluble gel matrix into bile acid-based microcapsules for the delivery of viable beta-cells of the pancreas, in diabetes treatment: biocompatibility and functionality studies

机译:在糖尿病治疗中,将水溶性凝胶基质掺入胆汁酸基微胶囊中,以递送胰腺的活β细胞:生物相容性和功能性研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In recent studies, we microencapsulated pancreatic beta-cells using sodium alginate (SA) and poly-L-ornithine (PLO) and the bile acid, ursodeoxycholic acid (UDCA), and tested the morphology and cell viability post-microencapsulation. Cell viability was low probably due to limited strength of the microcapsules. This study aimed to assess a beta-cell delivery system which consists of UDCA-based microcapsules incorporated with water-soluble gel matrix. The polyelectrolytes, water-soluble gel (WSG), polystyrenic sulphate (PSS), PLO and polyallylamine (PAA) at ratios 4:1:1:2.5 with or without 4 % UDCA, were incorporated into our microcapsules, and cell viability, metabolic profile, cell functionality, insulin production, levels of inflammation, microcapsule morphology, cellular distribution, UDCA partitioning, biocompatibility, thermal and chemical stabilities and the microencapsulation efficiency were examined. The incorporation of UDCA with PSS, PAA and WSG enhanced cell viability per microcapsule (p < 0.05), cellular metabolic profile (p < 0.01) and insulin production (p < 0.01); reduced the inflammatory release TNF-alpha (p < 0.01), INF-gamma (p < 0.01) and interleukin-6 (IL-6) (p < 0.01); and ceased the production of IL-1 beta. UDCA, PSS, PAA and WSG addition did not change the microencapsulation efficiency and resulted in biocompatible microcapsules. Our designed microcapsules showed good morphology and desirable insulin production, cell functionality and reduced inflammatory profile suggesting potential applications in diabetes.
机译:在最近的研究中,我们使用海藻酸钠(SA)和聚L-鸟氨酸(PLO)以及胆汁酸,熊去氧胆酸(UDCA)微囊化了胰腺β细胞,并测试了微囊化后的形态和细胞活力。细胞活力低可能是由于微胶囊的强度有限。这项研究旨在评估一个β细胞传递系统,该系统由掺有水溶性凝胶基质的基于UDCA的微胶囊组成。含或不含4%UDCA的比例为4:1:1:2.5的聚电解质,水溶性凝胶(WSG),聚苯乙烯硫酸盐(PSS),PLO和聚烯丙胺(PAA)被掺入我们的微胶囊中,并且细胞活力,代谢概况,细胞功能,胰岛素产生,炎症水平,微胶囊形态,细胞分布,UDCA分配,生物相容性,热和化学稳定性以及微囊化效率进行了检查。 UDCA与PSS,PAA和WSG的结合提高了每个微胶囊的细胞活力(p <0.05),细胞代谢特征(p <0.01)和胰岛素产生(p <0.01);降低炎症释放TNF-α(p <0.01),INF-γ(p <0.01)和白细胞介素6(IL-6)(p <0.01);并停止了IL-1 beta的生产添加UDCA,PSS,PAA和WSG不会改变微囊化效率,并导致了生物相容性微囊。我们设计的微胶囊显示出良好的形态和理想的胰岛素产生,细胞功能以及减少的炎症状况,提示其在糖尿病中的潜在应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号